13 Jul 2017 11:39
'This announcement contains inside information.'
Collagen Solutions Plc
(the "Company")
Director/PDMR Dealing
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that Options over ordinary shares of 1p each, as noted below in the Company ("Ordinary Shares") were granted on 12 July 2017.
The Options have an exercise period of ten years from grant and have an exercise price per Option of 5.25p. The Options vest in full after the normal vesting date of 12 July 2020, upon the closing middle market price per Ordinary Share achieving 10p and positive cash flow from operations being sustained for a period of six months.
Director/PDMR | Position | Number of Ordinary Shares options granted |
Jamal Rushdy | Chief Executive Officer | 1,700,000 |
Gillian Black | Chief Financial Officer | 1,700,000 |
Christian Wattengel | PDMR / VP Global R&D | 500,000 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||||
a)
| Name
| 1. Jamal Rushdy 2. Gillian Black 3. Christian Wattengel
| ||||||||
2
| Reason for the notification
| |||||||||
a)
| Position/status
| 1. Chief Executive Officer 2. Chief Financial Officer 3. PDMR / VP Global R&D | ||||||||
b)
| Initial notification /Amendment
| Initial | ||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||||
a)
| Name
| Collagen Solutions Plc | ||||||||
b)
| LEI
| N/a | ||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Option to acquire 1p ordinary shares in Collagen Solutions Plc
N/a
| ||||||||
b)
| Nature of the transaction
| Grant of options | ||||||||
c)
| Price(s) and volume(s)
|
| ||||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
N/a
N/a
| ||||||||
e)
| Date of the transaction
| 12 July 2017 | ||||||||
f)
| Place of the transaction
| Outside a trading venue | ||||||||
About Collagen Solutions:
Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.
Enquiries:
Collagen Solutions Plc | Contact via Walbrook | ||
Jamal Rushdy, Chief Executive Officer |
| ||
Gill Black, Chief Financial Officer |
| ||
|
| ||
Cenkos Securities plc (Nominated Adviser and Broker) Stephen Keys Steve Cox Callum Davidson | Tel: 0207 397 8900
| ||
|
| ||
Walbrook PR | Tel: 020 7933 8780 or collagen@walbrookpr.com | ||
Mike Wort | Mob: 07900 608 002 | ||
Anna Dunphy | Mob: 07876 741 001 | ||